Merck's Keytruda First-Line Improves Esophageal Cancer Survival
Regardless Of Histology, When Combined With Chemotherapy
Merck & Co is working hard to extend the indications for Keytruda, and reports the checkpoint inhibitor significantly improves overall survival and PFS when combined with chemotherapy in the first-line treatment of metastatic esophageal cancer.
You may also be interested in...
A new frontier for IO therapies in gastric/gastroesophageal cancers is opening up on positive data for two leading checkpoint inhibitors in first-line advanced disease where BMS’s Opdivo looks likely to have an advantage over Merck & Co’s Keytruda.
Opdivo showed a 23% fall in the risk of death and 2.5-month improvement in median overall survival compared to chemotherapy in Phase III esophageal cancer trial.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.